Abstract
The authors induced autologous cytotoxic T lymphocytes (CTLs) directly from peripheral blood lymphocytes by preparing a coculture of minced tissue fragments of glioblastoma multiforme (GBM) with interleukins-1, -2, -4, and -6 and interferon-gamma in RHAM alpha medium containing 5% autologous plasma for 2 weeks. At the end of this period, the frequencies of CD3+, CD4+, CD8+, and CD16+ lymphocytes were 95% to 99%, 40% to 62%, 37% to 38%, and 0.2%, respectively. The lymphocytes killed 82% to 100% of the GBM cells within 48 hours at an effector-to-target cell ratio of 1.67, whereas in a separate coculture, autologous lymphokine-activated killer (LAK) cells killed only 33% of GBM cells under the same conditions. The lymphocytes showed no cytotoxicity against LAK-sensitive Daudi cells, natural killer-sensitive K562 cells or autologous fibroblasts grown from the brain tumor, although they did show slight cytotoxicities against allogeneic GBM cell lines. These results lead the authors to suggest that the lymphocyte population contains specific CTLs for autologous brain tumor cells and that these CTLs could be effective in adoptive immunotherapy to combat brain tumor.
References
Dec 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·I HeronK Berg
Jun 1, 1979·The Journal of Experimental Medicine·S GillisK A Smith
Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·K KawaiT Ohno
Jun 1, 1989·The Journal of Experimental Medicine·B MukherjiM T Ergin
Apr 15, 1987·International Journal of Cancer. Journal International Du Cancer·T E RobertsM Moore
Apr 1, 1988·Annals of Internal Medicine·R I FisherK A Margolin
Nov 1, 1988·Journal of Neurosurgery·S MiyatakeM Hanaoka
Sep 19, 1986·Science·S A RosenbergR Lafreniere
Apr 9, 1987·The New England Journal of Medicine·S A RosenbergJ T Rubin
Dec 5, 1985·The New England Journal of Medicine·S A RosenbergJ T Vetto
Feb 1, 1985·European Journal of Immunology·S CarrelL Giuffrè
Apr 1, 1982·The Journal of Experimental Medicine·F Plata
Jun 1, 1982·The Journal of Experimental Medicine·E A GrimmS A Rosenberg
Jan 1, 1984·Cancer Immunology, Immunotherapy : CII·E KedarS Mitelman
Oct 28, 1982·Nature·D WallachM Revel
Aug 1, 1984·Cancer·H L Evans
Jan 1, 1982·Cancer·W A VeenhovenH O Nieweg
Apr 15, 1994·Cellular Immunology·M NakashimaZ Steplewski
Mar 1, 1995·Nature Medicine·S Q LiuT Ohno
Nov 1, 1994·Cancer Immunology, Immunotherapy : CII·S Q LiuT Ohno
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·T TakahashiT Yoshiki
Mar 5, 1993·Science·H TakahashiI Puisieux
Feb 1, 1993·Clinical Immunology and Immunopathology·C G Ioannides, T L Whiteside
Citations
Oct 6, 2009·Journal of Neuro-oncology·Lara DriggersMartin R Jadus
Nov 30, 1999·Immunology Letters·N S ZeineddineM R Jadus
Jan 1, 1997·Cytotechnology·T Ohno
Nov 13, 2008·Cytotechnology·K SaijoT Ohno
Aug 21, 2002·Journal of Neurosurgery·Minoru TanakaYukihiro Nakanishi
Jul 4, 2012·Neurosurgery Clinics of North America·Seunggu J HanAndrew T Parsa
Dec 1, 2009·Neurosurgery Clinics of North America·Seunggu J HanMichael Lim
Jul 27, 2002·Cellular Immunology·Ramon SanchezMartin R Jadus
Dec 16, 1998·Japanese Journal of Cancer Research : Gann·M KohyamaT Ohno
Jul 3, 1999·Japanese Journal of Cancer Research : Gann·H TsurushimaT Ohno
Jun 13, 2003·Microbiology and Immunology·Tadao Ohno
Sep 1, 2005·Journal of Neuro-oncology·Hideo TsurushimaTadao Ohno
Jan 25, 2005·International Journal of Urology : Official Journal of the Japanese Urological Association·Koji KawaiHideyuki Akaza